Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents

Journal of Medicinal Chemistry

Volumn 51, Issue 1, 2008, Pages 86-100

  Reddy, M V Ramana ^a   Mallireddigari, Muralidhar R ^a   Cosenza, Stephen C ^a   Pallela, Venkat R ^a   Iqbal, Nabisa M ^a   Robell, Kimberly A ^a   Kang, Anthony D ^a   Reddy, E Premkumar ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,6 TRIMETHOXYSTYRYL 3 HYDROXY 4 METHOXYBENZYLSULFONE; 2,4,6 TRIMETHOXYSTYRYL 3 O PHOSPHATE DISODIUM 4 METHOXYBENZYLSULFONE; 2,4,6 TRIMETHOXYSTYRYL 4 METHOXYBENZYLSULFONE; ANTINEOPLASTIC AGENT; BENZYL DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLINE; CYTOTOXIC AGENT; PACLITAXEL; STYRENE DERIVATIVE; STYRYLBENZYLSULFONE DERIVATIVE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TARGET CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; SULFONES; TOXICITY TESTS;

EID: 37849016327     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701077b     Document Type: Article

References (32)

1. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1, 222-231.
2. Sherr, C. J.; McCormick, F. The Rb and p53 pathways in cancer. Cancer Cell 2002, 2, 103-112.
3. Grana, X.; Reddy, E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKIs). Oncogene 1995, 11, 211-219.
4. Blagosklonny, M. V.; Pardee, A. B. The restriction point of the cell cycle. Cell Cycle 2002, 1, 103-105.
5. Hunter, T. Oncoprotein networks. Cell 1997, 88, 333-346.
6. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13, 261-291.
7. Donjerkovic, D.; Scott, D. W. Regulation of the G1 phase of the mammalian cell cycle. Cell Res. 2000, 10, 1-16.
8. O'Connor, P. M. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 1997, 29, 151-182.
9. Millard, S. S.; Kof, A. Cyclin-dependent kinase inhibitors in restriction point control, genomic stability and tumorigenesis. J. Cell. Biochem. 1998, 30-31, 37-42.
10. Mc Donald, E. R.; El-Diery, W. S. Check point genes in cancer. Ann. Med. 2001, 33, 113-122.
11. Ewen, M. E. Relationship between Ras pathways and cell cycle control. Prog. Cell Cycle Res. 2000, 4, 1-17.
12. Wang, T.; Wang, H.; Soong, Y. Paclitaxel-induced cell death. Cancer 2000, 88, 2619-2628.
13. (a) Reddy, M. V. R.; Reddy, S. Synthesis of α,β-unsaturated suflones. Acta Chim. Hung. 1984, 115, 269-271.
14. (b) Reddy, D. B.; Reddy, N. S.; Reddy, S.; Reddy, M. V. R.; Balasubramanyam, S. Preparation of styryl benzyl sulfones and 1,2-bis-(styrylsulfonyl-methyl)-4,5-dimethylbenzenes. Org. Prep. Proced. Int. 1988, 20, 205-212.
15. Reddy, A. K.; Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Mamidi, N. V. S. R.; Reddy, P. P.; Saibaba, V.; Reddy, N. J.; Suryaprakash, A.; Misra, P.; Vikramadithan, R. K.; Rajagopalan, R. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives. J. Med. Chem. 1999, 42, 3265-3278.
16. (a) Reddy, M. V. R.; Reddy, S.; Reddy, D. B. Facile method for the synthesis of 2-(arylsulfonyl)-1-phenyl-3-aryl-2-propen-1-ones. Sulfur Lett. 1987, 7, 43-48.
17. (b) Russell Llyod, B.; Anthony, D.; Chantal Renee, F.; Richard Francis, L. Novel Knoevenagel condensation of a β- keto sulfone and a β- carboalkoxy sulfone. Sulfur Lett. 1999, 23, 11-31.
18. (c) Reddy, M. M.; Venkat, R. P.; Reddy, E. P.; Reddy, M. V. R. Sequential reduction and dehydration of phenacyl-(E)-styryl sulfones to unsymmetrical (E,E)-bis(styryl) sulfones. Synthesis 2005, 3639-3643.
19. (d) Touati, A.; Cazaux, L. Synthesis of sulfonamides, sulfonates and thiosulfonates which are inhibitors of coniferyl alcohol dehydrogenase. J. Soc. Alger. Chim. 1996, 6, 39-52.
20. (a) Kendall, P. M.; Johnson, J. V.; Cook, C. E. Synthetic route to an aromatic analog of strigol. J. Org. Chem. 1979, 44, 1421-1424.
21. (b) Ronald, R. C.; Lansinger, T. S.; Lillie, T. S.; Wheeler, C. J. Total synthesis of frustulosin and aurocitrin. J. Org. Chem. 1982, 47, 2541-2549.
22. (c) Corey, E. J.; Venkateswarulu, A. Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives. J. Am. Chem. Soc. 1972, 94, 6190-6191.
23. Wolfrom, M. L.; Koos, E. W.; Bhat, H. B. Osage orange pigment. XV111. Synthesis of osajaxanthone. J. Org. Chem. 1967, 32, 1058-1060.
24. (a) Pettit, G. R.; Lippert, J. W. Antineoplastic agents. 429. Synthesis of the combretastatin A-1 and combretastatin B-1 prodrugs. AntiCancer Drug Des. 2000, 15, 203-216.
25. (b) Pettit, G. R.; Moser, B. R.; Boydl, M. R.; Schmidt, J. M.; Pettit, R. K.; Chapuis, J.-C. Antineoplastic agents. 460. Synthesis of combretastatin A-2 prodrugs. AntiCancer Drug Des. 2001, 16, 185-193.
26. (c) Pettit, G. R.; Grealish, M. P.; Jung, K.; Hamel, E.; Pettit, R. K.; Chapuis, J.-C.; Schmidt, J. M. Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J. Med. Chem. 2002, 45, 2534-2542.
27. Harker, W. G.; Sikic, B. I. Multidrug (pleiotropic) resistance in doxorubicin selected variants of the human sarcoma cell line MESSA. Cancer Res. 1985, 45, 4091-4096.
28. Fujimori, A.; Arker, W. G.; Kohlhagen, G.; Hoki, Y.; Pommier, Y. Mutation at the catalytic site of topoisomerase 1 in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 1995, 55, 1339-1346.
29. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin. Oncol. 1992, 19, 622-663.
30. Soldant, C.; Scovassi, A. I. Poly(ADP-ribose) polymerase-1 clevage during apoptosis: an update. Apoptosis 2002, 7, 321-328.
31. Park, I. W.; Reddy, M. V. R.; Reddy, E. P.; Groopman, J. E. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene 2007, 26, 5635-5642.
32. Cosenza, S. C.; Baker, S. J.; Reddy, E. P. Methods for Oncogenic Detection. In Cell Growth, Differentiation and Senescence; Studzinski, G. P., Ed.; Oxford University Press: Oxford, U.K., 1999; 161-176.